Michelle Dawson posts

Post published on Twitter/X on 29 Nov 2022 14:41

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms
Open original post

Information about the link integrated into the post

Clinical trial

Fenix Innovation Group, Neurotech International Limited, Monash Health (2022). Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder. ClinicalTrials.gov. Fenix Innovation Group.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Fenix Innovation Group, Neurotech International Limited, Monash Health (2022). Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder. ClinicalTrials.gov. Fenix Innovation Group.

Publication date
30 Nov 2022
Identifier
NCT05626959
Authors
Fenix Innovation Group, Neurotech International Limited, Monash Health
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Fenix Innovation Group
Metadata source
clinicaltrials.gov

Abstract

This is an 18 to 54 week study assessing the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on the severity of autism spectrum disorder in young people.

Open source Link to cited source